Author:
Kumar Neeraj,Devineni Subba Rao,Gajjala Prasad Reddy,Gupta Dharmendra Kumar,Bhat Sandesh,Kumar Rajesh,Dubey Shailendra Kumar,Kumar Pramod
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference19 articles.
1. European Medicines Agency, Assessment Report for Brilique, January, 2011. FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes, July 25, 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm (accessed 02.12.).
2. FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes, July 25, 2011. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm (accessed 02.12.).
3. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation;Van Giezen;J. Thromb. Haemost.,2009
4. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist;Husted;Cardiovasc. Ther.,2009
5. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin;Husted;Eur Heart J,2006
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献